- 22nd November 2011, Prague – 32 participants
- 3rd February 2012, Warsaw – 27 participants
- 12th April 2013 Bratislava
- 26th April 2o13 Prague
CECOG has now finished two studies (the CORE -1 and the CORE -2 Study) which have applied EGFR Inhibitors in metastatic Colorectal Cancer. CORE 1 compared FOLFOX and FOLFIRI both in combination with Cetuximab, CORE 2 investigated the ability to administer Cetuximab every two weeks.
Whereas the first trial was published in the World Journal of Gastroenterology, the second is still being evaluated regarding the results, but has provided some very interesting preliminary data. In order to further expand on these activities, CECOG is planning to hold educational meetings on the issue within our area.